Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC

ARK Investment Management LLC boosted its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 11.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,910,191 shares of the company’s stock after purchasing an additional 802,268 shares during the quarter. ARK Investment Management LLC owned approximately 8.91% of Personalis worth $51,574,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new stake in shares of Personalis in the second quarter valued at approximately $30,000. Ameritas Investment Partners Inc. bought a new position in Personalis in the 2nd quarter worth approximately $34,000. BNP Paribas Financial Markets increased its position in Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Farther Finance Advisors LLC bought a new stake in Personalis during the 3rd quarter valued at $66,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Personalis during the 2nd quarter worth $75,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on PSNL shares. HC Wainwright upped their price target on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Morgan Stanley upped their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. BTIG Research lifted their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Needham & Company LLC boosted their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Finally, Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.14.

Personalis Stock Performance

Shares of PSNL opened at $8.93 on Thursday. The firm has a market cap of $934.35 million, a PE ratio of -9.81 and a beta of 2.02. The firm’s 50 day moving average price is $8.85 and its 200 day moving average price is $8.07. Personalis, Inc. has a twelve month low of $2.83 and a twelve month high of $11.50.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.05. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%.The company had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. On average, sell-side analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.